medigraphic.com
Boletín Médico del Hospital Infantil de México

2019, Number 4

<< Back Next >>

Bol Med Hosp Infant Mex 2019; 76 (4)

Tofacitinib as a treatment of alopecia areata in adolescents

Morales-Miranda AY, Bueno-Arias GM, Aguirre-Félix ÓG, Tovar-Franco, ÓG

Language: Spanish
References: 23
Page: 182-187
PDF size: 245.70 Kb.


ABSTRACT

Background: Currently, no standardized treatment for severe alopecia areata (AA) exists. Numerous successful cases of the use of tofacitinib have been reported in the world literature, but not in Mexico. Four Mexican adolescents with severe AA treated with oral tofacitinib are reported in the present work. Methods: Series of cases of adolescents with severe AA treated with oral tofacitinib. The severity of alopecia tool was used to determine the response to treatment. Results: Four patients from 13 to 19 years old, were included. In all cases, hair growth was observed, and the alopecia severity decreased after the treatment with tofacitinib. In two patients, an intermediate response (from 51 to 90%) was observed; in the other, a moderate response (from 6 to 50%) was observed, without serious adverse effects. The limitations of the study were the small sample size and the retrospective nature of data collection. Conclusions: Tofacitinib showed to be a good treatment alternative for AA, total and universal, refractory to other therapies.


REFERENCES

  1. Strazzulla LC, Wang E, Avila L, Lo Sicco K, Brinster N, Crristiano A, et al. Alopecia areata: disease characteristics, clinical evaluation and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78:1-12.

  2. Gip L, Lodin A, Molin L. Alopecia areata. A follow-up investigation of outpatient material. Acta Derm Venereol (Stockh). 1969;49:180-8.

  3. Jang YH, Hong NS, Moon SY, Eun DH, Lee WK, Chi SG, et al. Long-term prognosis of alopecia totalis, universalis. A longitudinal study with more than 10 years of follow-up: better than reported. Dermatology. 2017; 233:250-6.

  4. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55:438-41.

  5. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916-26.

  6. Gupta AK, Carviel J, Abramovits W. Treating alopecia areata: current practices versus new directions. Am J Clin Dermatol. 2016;18:67-75.

  7. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549-66.

  8. Xing L, Dai Z, Jabbari A, Cerise J, Higgins C, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043-9.

  9. Wesh K, Holstein J, Laurence A, Ghoreschi K. Targeting Jak/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47:1096-107.

  10. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. 2014; 134:2988-90.

  11. Chiang A, Ortenzio F, Juhasz ML, Yu V, Mesinkovska NA. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature. JAAD Case Rep. 2018;4:733-6.

  12. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76:22-8.

  13. Craiglow BG, Liu LY, King BA. Tofacitinib for treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76:29-32.

  14. Patel NU, Oussedik E, Grammenos A, Pichardo-Geisinger R. A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg. 2018;22:439-42.

  15. Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol. 2018;78:1207-9.

  16. McKesey J, Blankenship DW, Jamison M, DeWitt C. Alopecia universalis successfully treated with tofacitinib. J Am Acad Dermatol. 2017;76:AB38.

  17. Mrowietz U, Gerdes S, Gläser R, Schröder O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. 2017;97:283-4.

  18. Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF. Treatment of alopecia areata with tofacitinib. JAMA Dermatol. 2017;153:600-2.

  19. Castelo-Soccio LD. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol. 2017;76:754-5.

  20. Scheinberg M, Ferreira SB. Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med. 2016;165:750-1.

  21. Castañeda O, Romero FJ, Salinas A, Citera G, Mysler E, Rillo O. Safety of tofacitinib in the treatment of rheumatoid arthritis in Latin America compared with the rest of the world population. J Clin Rheumatol. 2017; 23:193-9.

  22. US Food and Drug Administration Advisory Committee Meeting Tofacitinib for the treatment of rheumatoid arthritis: NDA 203214 briefing document; 2018. Disponible en: https://www.fda.gov/media/111372/download.

  23. Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1:e89776.




2020     |     www.medigraphic.com